Hologic, Inc., Siemens Healthcare GmbH, and F. Hoffmann-La Roche Ltd. have dominated the Global Breast Cancer Diagnostics Market in 2022

Global Breast Cancer Diagnostics Market is expected to grow with the CAGR of 9.2% in the forecast period of 2023 to 2030. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-breast-cancer-diagnostics-market

Global breast cancer diagnostics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global breast cancer diagnostics market are introducing strong range of products and services and adopting strategic initiative such as acquisition, agreement, business expansion, announcement, achievement, and innovation into the market. This helped companies to maximize the sales with enhanced services portfolio.

For instance;

• In December 2022, Hologic, Inc. announced new study data showing that the Breast Cancer Index test identified for patients with early-stage, hormone-receptor positive (HR+) breast cancer is benefiting from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT). The translational study results were featured in the official press program at the 2022 San Antonio Breast Cancer Symposium (SABCS). This has helped company to show its study results for expansion of product.

Hologic, Inc. is the market leader in global breast cancer diagnostics market globally. The other player in this market are Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., Abbott, Exact Sciences Corporation, BD., Thermo Fisher Scientific Inc., Illumina, Inc., FUJIFILM Corporation, General Electric, Cepheid., Bio-Rad Laboratories, Inc., Biocept, Inc., bioMérieux SA, Myriad Genetics, Inc., NanoString., OncoStem., Provista Diagnostics. And Abacus ALS.

Hologic, Inc.

Hologic, Inc. Is headquartered in Massachusetts, U.S. and was founded in 1985. The company is focused on providing womens oncology related products and services for healthy lifestyle. It provides various products such as breast health, gynecological health, sexual health, body composition, and skeletal health.

For instance;

• In December 2022, Hologic, Inc. announced new study data showing that the Breast Cancer Index test identified for patients with early-stage, hormone-receptor positive (HR+) breast cancer is benefiting from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT). The translational study results were featured in the official press program at the 2022 San Antonio Breast Cancer Symposium (SABCS). This has helped company to show its study results for expansion of product.

The company has a presence in Europe, Asia-Pacific, Americas, and Middle East and Africa.

Siemens Healthcare GmbH

Siemens Healthcare GmbH is headquartered in Bavaria, Germany, and was founded in 1896. The company focuses on providing innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine as well as digital health and enterprise services. It provides various products & services in clinical fields. The company has a presence in Europe, Asia-Pacific, Americas, and Middle East and Africa.

For instance;

• In November 2022, Siemens Healthineers Gmbh and Atrium Health, a leading healthcare provider known for cancer and cardiac care programs, has announced a multi-year value partnership. This strategic agreement focuses on improving access to care in Atrium Health's service area in the United States, improving health equity and increasing economic mobility. Atrium Health is acquiring more than $140 million in equipment and devices from Siemens Healthineers. This has helped the company to expand their business.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. is headquartered in Basel, Switzerland & was founded in 1896. The company focuses on providing of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. It provides various products in pharma and diagnostics. The company has a presence in North America, Europe, Asia-Pacific, South America, Middle East and Africa.

For instance;

• In October 2022, F. Hoffmann-La Roche Ltd announced US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low HER2 expression ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) developed and commercialised by AstraZeneca and Daiichi Sankyo. This has helped company to showcase its progress in breast cancer diagnosis.